The estimated Net Worth of James Stambaugh is at least 1.29 百万$ dollars as of 2 September 2016. James Stambaugh owns over 4,000 units of Intersect ENT Inc stock worth over 564,800$ and over the last 10 years James sold XENT stock worth over 724,696$.
James has made over 14 trades of the Intersect ENT Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently James sold 4,000 units of XENT stock worth 64,000$ on 2 September 2016.
The largest trade James's ever made was exercising 20,000 units of Intersect ENT Inc stock on 6 November 2015 worth over 9,600$. On average, James trades about 5,423 units every 36 days since 2015. As of 2 September 2016 James still owns at least 20,000 units of Intersect ENT Inc stock.
You can see the complete history of James Stambaugh stock trades at the bottom of the page.
James's mailing address filed with the SEC is 1555 Adams Dr, Menlo Park, CA 94025, USA.
Over the last 10 years, insiders at Intersect ENT Inc have traded over 22,664,783$ worth of Intersect ENT Inc stock and bought 58,846 units worth 713,631$ . The most active insiders traders include Rick D Anderson、Lisa D Earnhardt、W Anthony Vernon. On average, Intersect ENT Inc executives and independent directors trade stock every 18 days with the average trade being worth of 344,556$. The most recent stock trade was executed by Frederic H Moll on 19 January 2021, trading 12,500 units of XENT stock currently worth 9,000$.
Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company's steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company's unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company's PROPEL® and SINUVA® sinus implants and extend its geographic reach.
Intersect ENT Inc executives and other stock owners filed with the SEC include: